Vor Biopharma (NYSE:VOR) Downgraded by Citizens Jmp to “Hold”

Vor Biopharma (NYSE:VOR) was downgraded by analysts at Citizens Jmp from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Friday,Zacks.com reports.

Other analysts have also recently issued reports about the company. Wedbush restated a “neutral” rating and issued a $0.40 target price (down from $7.00) on shares of Vor Biopharma in a research report on Thursday. Stifel Nicolaus reduced their price objective on shares of Vor Biopharma from $12.00 to $5.00 and set a “buy” rating for the company in a report on Friday, March 21st. JMP Securities reiterated a “market perform” rating and issued a $6.00 target price on shares of Vor Biopharma in a research report on Friday. Oppenheimer restated an “outperform” rating and set a $8.00 price target on shares of Vor Biopharma in a research report on Friday, March 21st. Finally, Baird R W cut shares of Vor Biopharma from a “strong-buy” rating to a “hold” rating in a report on Thursday. Six research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $7.06.

Vor Biopharma Stock Performance

Shares of VOR opened at $0.15 on Friday. The firm has a fifty day moving average of $0.70 and a 200-day moving average of $0.97. The company has a market cap of $18.89 million, a price-to-earnings ratio of -0.09 and a beta of -0.21. Vor Biopharma has a 1 year low of $0.13 and a 1 year high of $1.87.

Institutional Trading of Vor Biopharma

Hedge funds and other institutional investors have recently modified their holdings of the business. Virtu Financial LLC acquired a new position in shares of Vor Biopharma in the 4th quarter valued at about $60,000. RA Capital Management L.P. increased its stake in Vor Biopharma by 74.3% in the 4th quarter. RA Capital Management L.P. now owns 39,646,039 shares of the company’s stock valued at $44,007,000 after buying an additional 16,897,159 shares during the period. Lynx1 Capital Management LP acquired a new position in shares of Vor Biopharma in the fourth quarter worth $707,000. XTX Topco Ltd purchased a new stake in shares of Vor Biopharma during the fourth quarter worth $80,000. Finally, GABELLI & Co INVESTMENT ADVISERS INC. acquired a new stake in Vor Biopharma during the fourth quarter valued at $33,000. Institutional investors and hedge funds own 97.29% of the company’s stock.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.